DAVID HARRY GODDARD
Medical Practice in Great Neck, NY
License number
Pennsylvania MD040344L
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
2
Great Neck, NY 11021
Pennsylvania
Pennsylvania
Personal information
See more information about DAVID HARRY GODDARD at radaris.comName
Address
Phone
49 Lorraine St, Plattsburgh, NY 12901
6078 Peach Tree St APT B, Harrisburg, PA 17111
5830 Mcphersons Pt, Livonia, NY 14487
459 Creek Rd, Pleasant Valley, NY 12569
63 Myers Rd, Godeffroy, NY 12729
Professional information
Method Of Treating Cd4+ T Cell Lymphopenia In Immuno-Compromised Patients
US Patent:
5728560, Mar 17, 1998
Filed:
Jun 14, 1996
Appl. No.:
8/663685
Inventors:
Robert G. L. Shorr - Edison NJ
Mike A. Clark - Big Pine Key FL
David H. Goddard - Great Neck NY
Mike A. Clark - Big Pine Key FL
David H. Goddard - Great Neck NY
Assignee:
Enzon, Inc. - Piscataway NJ
International Classification:
A61K 3843, C12N 900, C12N 978
US Classification:
435183
Abstract:
The present invention is directed to methods of treating CD4+ T cell lymphopenia in HIV-infected patients. The methods include administering an effective mount of adenosine deaminase or related enzymatic material to a patient in need thereof. In preferred aspects of the invention, the method is employed in conjunction with HIV-infected patients having CD4+ T cell levels of less than about 200/. mu. l. Effective amounts of the enzyme range from about 5 to about 50 IU/kg/week. In one particularly preferred aspect of the invention, the adenosine deaminase is conjugated to one or more strands of polyethylene glycol to prolonged activity in vivo.
Treatment Of Tumors
US Patent:
5602094, Feb 11, 1997
Filed:
Mar 29, 1994
Appl. No.:
8/219506
Inventors:
David Goddard - Great Neck NY
International Classification:
A61K 3809
US Classification:
514 12
Abstract:
Malignant gliomas are treated by modifying the eicosanoid biosynthetic pathway with reduction of the inhibitory effect of prostanoids on the cytotoxic activity of NK and LAK cells. Synthetic peptides, corresponding to shared sequences with phospholipase activating protein (PLAP), having the capacity to activate phospholipase A. sub. 2 (PLA. sub. 2), when administered in a delayed release delivery system, such as with agarose beads induce release of PGE. sub. 2, with significant tumor necrosis. A tumor model comprising an air pouch in the dorsum of rats is utilized for effective evaluation of the treatment, with tumor growth, treatment and evaluation of tumors grown therein.